Document:

Document

Execution Version

AMENDMENT NO. 1

This AMENDMENT NO. 1 (this “Amendment”), dated as of April 24, 2020 and effective as of the Amendment No. 1 Effective Date (as hereinafter defined), is made and entered into by and among TWIN RIVER WORLDWIDE HOLDINGS, INC., a Delaware corporation (the “Borrower”), the GUARANTORS, each REVOLVING LENDER party hereto, and CITIZENS BANK, N.A., as administrative agent for the Lenders under the Existing Credit Agreement (as hereinafter defined) (in such capacity, the “Administrative Agent”).
RECITALS:

WHEREAS, reference is hereby made to the Credit Agreement, dated as of May 10, 2019 (as amended, restated, amended and restated, replaced, supplemented, or otherwise modified prior to giving effect to the amendments contemplated by this Amendment, the “Existing Credit Agreement” and, after giving effect to the amendments contemplated by this Amendment, the “Credit Agreement”), among the Borrower, the Guarantors, the Lenders party thereto from time to time, the Administrative Agent, Citizens Bank, N.A., as collateral agent for the Secured Parties (as defined in the Credit Agreement), and the other parties thereto;

WHEREAS, the Borrower has requested certain amendments to and consents under the Existing Credit Agreement; and

WHEREAS, the Administrative Agent, the Borrower and the Revolving Lenders party hereto, constituting the Required Revolving Lenders, are willing to agree to such amendments and consents pursuant to Section 13.04(a)(vii) of the Existing Credit Agreement, subject to the terms and conditions set forth in this Amendment.

NOW, THEREFORE, in consideration of the premises and agreements, provisions, and covenants herein contained and other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the parties hereto agree as follows:

ARTICLE I

DEFINITIONS

SECTION 1.1 Definitions.  Except as otherwise expressly provided herein, capitalized terms used in this Amendment (including in the Recitals and the introductory paragraph above) shall have the meanings given in the Credit Agreement, and the rules of construction set forth in the Credit Agreement shall apply to this Amendment.

ARTICLE II

AMENDMENTS TO EXISTING CREDIT AGREEMENT

SECTION 2.1 Amendments to Existing Credit Agreement.  The following amendments to the Existing Credit Agreement shall take effect and become operative upon the Amendment No. 1 Effective Date:

(a)Section 1.01 of the Existing Credit Agreement is hereby amended by amending and restating the last sentence of the definition of “LIBO Base Rate” as follows:

Notwithstanding the foregoing, the LIBO Base Rate shall not be less than (i) with respect to the Term B Facility Loans, 0.00% and (ii) with respect to the Revolving Loans, 0.75%.

(b)Section 10.08 of the Existing Credit Agreement is hereby amended and replaced with the following (provided, however, that such amendments shall be disregarded for the purpose of any requirement under the Credit Agreement to be in compliance on a Pro Forma Basis with the Financial Maintenance Covenant (and Section 10.08 and related definitions as used for such purpose) for purposes of Sections 9.12(a)(iii), 10.01(n)(ii), 10.04(l), 10.04(m), 10.06(j), 10.06(k), 10.09(a)(ii) and 10.09(a)(iii) of the Credit Agreement):

Section 10.08.  Financial Maintenance Covenant.  

(a) Consolidated Total Net Leverage Ratio.

        (i) Solely for the benefit of the Lenders under the Revolving Facility, without the consent of the Required Revolving Lenders, Borrower shall not permit the Consolidated Total Net Leverage Ratio as of the last day of any fiscal quarter of Borrower commencing with (i) the first complete fiscal quarter ending after the Closing Date through the fiscal quarter ending December 31, 2020 to exceed 5.50 to 1.00, (ii) the fiscal quarter ending March 31, 2021 through the fiscal quarter ending December 31, 2021 to exceed 5.25:1.00; and (iii) the fiscal quarter ending March 31, 2022 and each fiscal quarter thereafter to exceed 5.00:1.00; provided that (1) the provisions of this Section 10.08(a)(i) shall not be applicable to any such fiscal quarter if on the last day of such fiscal quarter (A) the aggregate principal amount of Revolving Loans, Swingline Loans and Letters of Credit (excluding up to $2.5 million of issued and outstanding undrawn Letters of Credit) that are issued and/or outstanding is equal to or less than 30% of the Total Revolving Commitments and (B) there are not more than $250.0 million of Revolving Commitments in the aggregate in effect and (2) this Section 10.8(a)(i) shall not apply to the extent but only for so long as Section 10.8(a)(ii) is applicable in accordance with clause (2) of the proviso thereof, provided, however, that if the Leverage Covenant Relief Period is terminated in accordance with clause (ii) of the definition thereof, this Section 10.08(a)(i) shall apply for each fiscal quarter after the Qualifying Quarter.
        (ii) Notwithstanding Section 10.8(a)(i) above, but only for so long as each and every Leverage Covenant Relief Period Condition shall be satisfied for the duration of the Leverage Covenant Relief Period, then solely for the benefit of the Lenders under the Revolving Facility, without the consent of the Required Revolving Lenders, Borrower shall not permit the Consolidated Total Net Leverage Ratio as of the last day of any fiscal quarter of Borrower commencing with (i) the fiscal quarter ending March 31, 2021 to exceed 6.25:1.00; (ii) the fiscal quarter ending June 30, 2021 to exceed 6.00:1.00; (iii) the fiscal quarter ending September 30, 2021 to exceed 5.75:1.00; (iv) the fiscal quarter ending December 31, 2021 to exceed 5.50:1.00 and (v) the fiscal quarter ending March 31, 2022 and each fiscal quarter thereafter to exceed 5.00:1.00; provided that (1) 

2

the provisions of this Section 10.08(a)(ii) shall not be applicable to any such fiscal quarter if on the last day of such fiscal quarter (A) the aggregate principal amount of Revolving Loans, Swingline Loans and Letters of Credit (excluding up to $2.5 million of issued and outstanding undrawn Letters of Credit) that are issued and/or outstanding is equal to or less than 30% of the Total Revolving Commitments and (B) there are not more than $250.0 million of Revolving Commitments in the aggregate in effect and (2) for the avoidance of doubt, (I) if at any time during the Leverage Covenant Relief Period, a default shall be made in the due observance or performance by Borrower or any Restricted Subsidiary of any Leverage Covenant Relief Period Condition or (II) Borrower shall fail to deliver the Compliance Certificate and Section 9.04 Financials in respect of the fiscal quarter ending March 31, 2021 on or prior to the dates required by this Agreement, then this Section 10.08(a)(ii) shall be null and void and shall be deemed to not have applied in respect of any Test Period ending during the Leverage Covenant Relief Period and (3) if the Leverage Covenant Relief Period is terminated in accordance with clause (ii) of the definition thereof, then the maximum Consolidated Total Net Leverage Ratio levels for each fiscal quarter after the Qualifying Quarter shall be those as in effect and set forth in Section 10.08(a)(i).

(b) Section 10.08 Defined Terms. As used in this Section 10.08, the following terms shall have the following meanings:

        (i) “Additional Specified Covenant Relief Period Acquisitions” shall mean the acquisition by the Borrower or its Restricted Subsidiaries of (i) the entities operating the Eldorado Resort Casino Shreveport and the Montbleu Resort Casino pursuant to and in accordance with that certain Equity Purchase Agreement, dated as of April 24, 2020 (the “Shreveport Acquisition Agreement”), among Affiliates of Eldorado Resorts, Inc. (“Eldorado”), the Borrower, Twin River Management Group, Inc., a Delaware corporation (“TRMG”) and the other parties party thereto and (ii) the casino, hotel and related operations and assets at the property known as Bally’s Park Place pursuant to that certain Asset Purchase Agreement, dated as of April 24, 2020 (the “Bally’s Acquisition Agreement” and, together with the Shreveport Acquisition Agreement, the “Additional Specified Covenant Relief Period Acquisition Agreements”), by and between Bally’s Park Place LLC and TRMG.

        (ii) “Leverage Covenant Relief Period” shall mean the period commencing on the Leverage Covenant Relief Period Commencement Date and ending on the earlier of (i) the date on which Administrative Agent receives from Borrower the Compliance Certificate and Section 9.04 Financials in respect of the fiscal quarter ending March 31, 2021 and (ii) the date that the Administrative Agent receives a Leverage Covenant Relief Period Termination Notice from Borrower.

        (iii) “Leverage Covenant Relief Period Commencement Date” shall mean the “Amendment No. 1 Effective Date” under and as defined in the Amendment No. 1, dated as of April 24, 2020, among Borrower, the Guarantors party thereto, the Revolving Lenders party thereto and Administrative Agent.

3

        (iv) “Leverage Covenant Relief Period Conditions” shall mean, during the Leverage Covenant Relief Period, the Borrower:

  (a) shall not, and shall not permit any of its Restricted Subsidiaries to, (1) designate any Subsidiary of the Borrower as an Unrestricted Subsidiary pursuant to Section 9.12, (2) designate any Restricted Subsidiary of the Borrower as an Immaterial Subsidiary pursuant to Section 9.13, other than any Restricted Subsidiary that is newly formed (but not acquired) by the Borrower or any of its Restricted Subsidiaries that satisfies all the criteria to be designated as an Immaterial Subsidiary under the definition thereof and Section 9.13, (3) make any Investment (i) pursuant to Section 10.04(d) by any Credit Party in any Person that is not a Credit Party, (ii) pursuant to Section 10.04(i) other than (A) the Specified Covenant Relief Period Acquisitions and the Additional Specified Covenant Relief Period Acquisitions and (B) other Permitted Acquisitions solely to the extent the consideration therefor consists solely of Equity Interests of Borrower issued to the seller(s) in such Permitted Acquisition, (iii) pursuant to Section 10.04(k) in excess of $10.0 million in the aggregate during the Leverage Covenant Relief Period, (iv) pursuant to Section 10.04(h), other than Investments made in reliance on Section 10.04(h)(i) in an amount not to exceed $1.0 million in the aggregate during the Leverage Covenant Relief Period or (v) pursuant to Section 10.04(l), (m), (s), (t) or (x), (4) make any Restricted Payment pursuant to Section 10.06(i), (j), (k), (m) or (o) or (5) make any Junior Prepayments pursuant to Section 10.09(a)(i), (a)(ii), (a)(iii) or (a)(xii); 

        (b) shall not permit the Liquidity at the last day of any month, commencing with the first calendar month ending after the Amendment No. 1 Effective Date and through and including March 31, 2021 (or if the Leverage Covenant Relief Period has ended prior to March 31, 2021 pursuant to clause (ii) of the definition thereof, the last day of the calendar month immediately preceding such termination), to be less than the Minimum Liquidity Amount at such time; and 

        (c) shall as soon as available and in any event within 10 Business Days following the last day of each calendar month occurring during the Financial Covenant Relief Period, furnish a certificate of a Responsible Officer of Borrower setting forth in reasonable detail the computations necessary to determine whether Borrower and its Restricted Subsidiaries were in compliance with the covenants set forth in Section 10.08(b) as of the last day of the calendar month to which the certificate relates.

        (v) “Leverage Covenant Relief Period Termination Notice” shall mean a certificate of a Responsible Officer of Borrower that is delivered to Administrative Agent (a) stating that Borrower irrevocably elects (i) to terminate the Leverage Covenant Relief Period effective as of the date on which Administrative Agent receives such Covenant Relief Period Termination Notice and (ii) that commencing with the first fiscal quarter ending after the Qualifying 

4

Quarter, the Financial Maintenance Covenants set forth in Section 10.08 shall be governed by clauses (a)(i) thereof (instead of clause (a)(ii) thereof) and (b) certifying that Borrower and its Restricted Subsidiaries would have been in compliance with the Financial Maintenance Covenants (as set forth in clause (a)(i) of Section 10.08) as of the most recent Calculation Date if such Financial Maintenance Covenants had been applicable (the fiscal quarter ending on such Calculation Date, the “Qualifying Quarter”), and setting forth in reasonable detail the computations necessary to determine such compliance.

        (vi) “Liquidity” shall mean, on any date, the amount equal to (a) the sum of (x) unrestricted cash and Cash Equivalents of Borrower and its Restricted Subsidiaries (regardless of whether held in a Collateral Account), plus (y) cash and Cash Equivalents of Borrower and its Restricted Subsidiaries that are restricted in favor of the Obligations (which may include cash and Cash Equivalents securing other Indebtedness secured by a Lien on the Collateral), plus (b) the aggregate Unutilized R/C Commitments of all Revolving Lenders, minus (c) the Specified Covenant Relief Period Acquisition Liquidity Reserve.

        (vii) “Minimum Liquidity Amount” shall mean (a) from the Amendment No. 1 Effective Date through and including May 31, 2020, $75.0 million, (b) from June 1, 2020 through and including June 30, 2020, $65.0 million, (c) from July 1, 2020 through and including July 31, 2020, $55.0 million, and (d) from and after August 1, 2020 through and including March 31, 2021, $50.0 million.

        (viii) “Specified Covenant Relief Period Acquisition” shall mean the acquisition by the Borrower or its Restricted Subsidiaries of the equity interests of Rainbow Casino Vicksburg Partnership, L.P. and IOC-Kansas City, Inc. pursuant to and in accordance with that certain Equity Purchase Agreement, dated as of July 10, 2019, among Affiliates of Eldorado, TRMG, the Borrower and Eldorado.

        (ix) “Specified Covenant Relief Period Acquisition Liquidity Reserve” shall mean (a) at any time prior to the earlier of (i) the consummation of the Specified Covenant Relief Period Acquisition and (ii) the termination of the Specified Covenant Relief Period Acquisition in accordance its terms, $230.0 million and (b) from and after the earlier of (i) the consummation of the Specified Covenant Relief Period Acquisition and (ii) the termination of the Specified Covenant Relief Period Acquisition in accordance with its terms, $0.0.

(c) Notwithstanding anything to the contrary in the definition of “Consolidated EBITDA”, solely for purposes of Section 10.08(a)(ii), Consolidated EBITDA for the Test Period ending March 31, 2021 shall be deemed to be Consolidated EBITDA for the fiscal quarters ending December 31, 2020 and March 31, 2021 multiplied by 2, and (ii) Consolidated EBITDA for the Test Period ending June 30, 2021 shall be deemed to be Consolidated EBITDA for the fiscal quarters ending December 31, 2020, March 31, 2021 and June 30, 2021 multiplied by 4/3.

5

(d) Notwithstanding anything to the contrary in the definition of “Consolidated EBITDA”, solely for purposes of (A) any Leverage Covenant Relief Period Termination Notice and (B) Section 10.08(i) if the Leverage Covenant Relief Period is terminated in accordance with clause (ii) of the definition thereof, (i) Consolidated EBITDA for the Test Period ending on the last day of the Qualifying Quarter, shall be deemed to be, at the Borrower’s election, (1) Consolidated EBITDA for the four fiscal quarter period ending on the last day of the Qualifying Quarter, (2) Consolidated EBITDA for the three fiscal quarter period ending on the last day of the Qualifying Quarter multiplied by 4/3 or (3) Consolidated EBITDA for the two fiscal quarter period ending on the last day of the Qualifying Quarter multiplied by 2, and (ii) Consolidated EBITDA for the Test Period ending on the last day of the fiscal quarter immediately following the Qualifying Quarter shall be deemed to be (1) if the Borrower elected to use clause (i)(1) or (i)(2) above, Consolidated EBITDA for the four fiscal quarter period ending on the last day of the fiscal quarter immediately following the Qualifying Quarter and (2) if the Borrower elected to use clause (i)(3) above, Consolidated EBITDA for the three fiscal quarter period ending on the last day of the fiscal quarter immediately following the Qualifying Quarter multiplied by 4/3.

(e) For the avoidance of doubt, only the consent of the Required Revolving Lenders shall be required to (and only the Required Revolving Lenders, shall have the ability to) amend, waive or modify the covenants set forth in this Section 10.08 (including any amendment or modification of any defined terms as used in this Section 10.08).

(c)Annex B-1 of the Existing Credit Agreement is hereby amended by inserting the following at the end thereof:
; provided, that at all times during the Leverage Covenant Relief Period the Applicable Fee Percentage for Revolving Loans shall be based on Level I.
(d) Annex B-2 of the Existing Credit Agreement is hereby amended by inserting the following at the end thereof:
; provided, that at all times during the Leverage Covenant Relief Period the Applicable Margin for Revolving Loans and Swingline Loans shall be based on Level I.

ARTICLE III

CONSENT OF REQUIRED REVOLVING LENDERS

SECTION 3.1 Pursuant to Section 13.04(a)(vii)(D) of the Existing Credit Agreement, the Revolving Lenders party hereto, constituting the Required Revolving Lenders, hereby agree that, with respect to the funding of any Revolving Loan the proceeds of which are being used to fund any Additional Specified Covenant Relief Period Acquisition, so long as (1) the applicable Additional Specified Covenant Relief Period Acquisition Agreement shall not have been amended, waived or modified by Borrower (or its applicable Subsidiary) and Borrower (or its applicable Subsidiary) shall not have given any consent thereunder, in each case, that is materially adverse to the Lenders in their capacity as such in any such case without the prior written consent of the Required Revolving Lenders (such consent not to be unreasonably withheld, conditioned or delayed), (2) such Additional Specified Covenant 

6

Relief Period Acquisition is being consummated in all material respects in accordance with the applicable Additional Specified Covenant Relief Period Acquisition Agreement and (3) from April 24, 2020 to the date of the consummation of such Additional Specified Covenant Relief Period Acquisition, no “Material Adverse Effect” or “Business Material Adverse Effect” (as defined in the applicable Additional Specified Covenant Relief Period Acquisition Agreement) shall have occurred, then (a) the condition set forth in Section 7.02(a)(i) of the Existing Credit Agreement to funding a Revolving Loan the proceeds of which are being used to fund such Additional Specified Covenant Relief Period Acquisition shall be limited to the absence of any Event of Default specified in Section 11.01(b) or 11.01(c) of the Existing Credit Agreement or an Event of Default specified in Section 11.01(g) or 11.01(h) of the Existing Credit Agreement with respect to Borrower and (b) the condition set forth in Section 7.02(a)(ii) of the Existing Credit Agreement to funding a Revolving Loan the proceeds of which are being used to fund such Additional Specified Covenant Relief Period Acquisition shall be limited to the accuracy in all material respects of (x) the Specified Representations and (y) if applicable, the representations and warranties contained in the applicable Additional Specified Covenant Relief Period Acquisition Agreement as are material to the interests of the Lenders, but only to the extent that Borrower or any of its Affiliates have the right to terminate its or their obligations under the acquisition agreement for such Acquisition as a result of a breach of such representations and warranties in such acquisition agreement.

ARTICLE IV

REPRESENTATIONS AND WARRANTIES

SECTION 4.1 None of the execution, delivery and performance by any Credit Party of this Amendment nor the consummation of the transactions herein do or will (i) conflict with or result in a breach of, or require any consent (which has not been obtained and is in full force and effect) under (x) any Organizational Document of any Credit Party or (y) any applicable Requirement of Law (including, without limitation, any Gaming/Racing Law) or (z) any order, writ, injunction or decree of any Governmental Authority binding on any Credit Party or result in a breach of, or require termination of, any term or provision of any Contractual Obligation of any Credit Party or (ii) constitute (with due notice or lapse of time or both) a default under any such Contractual Obligation or (iii) result in or require the creation or imposition of any Lien (except for the Liens created pursuant to the Security Documents) upon any Property of any Credit Party pursuant to the terms of any such Contractual Obligation, except with respect to clauses (i)(y), (i)(z), (ii), or (iii) which would not reasonably be expected to result in a Material Adverse Effect.

SECTION 4.2 The representations and warranties contained in Article VIII of the Credit Agreement and in the other Credit Documents are true and correct in all material respects on and as of the Amendment No. 1 Effective Date (except where such representations and warranties expressly relate to an earlier date, in which case such representations and warranties were true and correct in all material respects as of such earlier date); provided that, any representation and warranty that is qualified as to “materiality,” “Material Adverse Effect” or similar language is (or was) true and correct in all respects.

7

ARTICLE V

CONDITIONS TO THE AMENDMENT NO. 1 EFFECTIVE DATE

This Amendment shall become effective on the date (the “Amendment No. 1 Effective Date”) on which each of the following conditions is satisfied or waived:

SECTION 5.1 Execution of Counterparts.  The Administrative Agent shall have received executed counterparts of this Amendment from each Credit Party, the Revolving Lenders constituting the Required Revolving Lenders, and the Administrative Agent.

SECTION 5.2    Corporate Documents.  The Administrative Agent shall have received:

(a)certified true and complete copies of the Organizational Documents of each Credit Party and evidence of all corporate or other applicable authority for each Credit Party (including board of directors (or other applicable governing authority) resolutions and evidence of the incumbency, including specimen signatures, of officers) with respect to the execution, delivery, and performance of this Amendment, certified as of the Amendment No. 1 Effective Date as complete and correct copies thereof by the Secretary or an Assistant Secretary of each such Credit Party (or the member or manager or general partner of such Credit Party, as applicable) (provided that, in lieu of attaching such Organizational Documents and/or evidence of incumbency, such certificate may certify that (i) since the Closing Date (or such later date on which the applicable Credit Party became party to the Credit Documents), there have been no changes to the Organizational Documents of such Credit Party and (ii) no changes have been made to the incumbency certificate of the officers of such Credit Party delivered on the Closing Date (or such later date referred to above));

(b)a certificate as to the good standing of each Credit Party as of a recent date, from the Secretary of State (or other applicable Governmental Authority) of its jurisdiction of formation; and

(c)an Officer’s Certificate of the Borrower, dated the Amendment No. 1 Effective Date, certifying that the conditions set forth in Section 5.3 hereof have been satisfied.

SECTION 5.3    No Default or Event of Default; Representations and Warranties True. Both immediately prior to this Amendment and also after giving effect to this Amendment:

(a)no Default or Event of Default shall have occurred and be continuing; and

(b)each of the representations and warranties made by the Credit Parties in Article VIII of the Credit Agreement, Article III hereof and in the other Credit Documents shall be true and correct in all material respects on and as of the Amendment No. 1 Effective Date (it being understood and agreed that any such representation or warranty which by its terms is made as of an earlier date shall be required to be true and correct in all material respects only as of such earlier date, and that any representation and warranty that is qualified as to “materiality,” “Material Adverse Effect” or similar language shall be true and correct in all respects on the applicable date).

SECTION 5.4        Fees.  

8

(a)Borrower shall have paid to Administrative Agent, for the account of each Revolving Lender under the Existing Credit Agreement that has delivered its executed counterpart to this Amendment prior to 7:00 p.m., New York City time, on April 24, 2020, a consent fee equal to 0.25% of the principal amount of such Lender’s Revolving Loans and Revolving Commitments under the Existing Credit Agreement.

(b)The Administrative Agent shall have received all fees and expenses required to be paid by the Borrower for which reasonably detailed invoices have been presented (including the reasonable fees and expenses of Latham & Watkins LLP), on or before the Amendment No. 1 Effective Date, but in no event less than two (2) Business Days prior to Amendment No. 1 Effective Date unless otherwise agreed to by Borrower.

ARTICLE VI

VALIDITY OF OBLIGATIONS AND LIENS

SECTION 6.1 Reaffirmation.  Each of the Credit Parties party hereto (a) acknowledges and agrees that all of such Credit Party’s obligations under the Security Documents and the other Credit Documents (as amended hereby) to which it is a party are reaffirmed and remain in full force and effect on a continuous basis as amended by this Amendment, (b) reaffirms each lien and security interest granted by it to the Collateral Agent for the benefit of the Secured Parties to secure the Secured Obligations and the guaranties of the Guaranteed Obligations made by it pursuant to the Existing Credit Agreement, and (c) acknowledges and agrees that the grants of liens and security interests by, and the guaranties of, the Credit Parties contained in the Existing Credit Agreement and the Security Documents are, and shall remain, in full force and effect, and continue to secure the Secured Obligations and guaranty the Guaranteed Obligations, after giving effect to this Amendment and the transactions contemplated hereby and thereby.

ARTICLE VII

MISCELLANEOUS

SECTION 7.1 Amendment, Modification and Waiver.  This Amendment may not be amended, modified or waived except by an instrument or instruments in writing signed and delivered on behalf of the Borrower and the Administrative Agent (acting at the direction of such Lenders as may be required under Section 13.04 of the Credit Agreement).

SECTION 7.2 Entire Agreement.  This Amendment (including the Schedules and Exhibits) and the other Credit Documents constitute the entire agreement among the parties with respect to the subject matter hereof and thereof and supersede all other prior agreements and understandings, both written and verbal, among the parties or any of them with respect to the subject matter hereof.  Each Revolving Lender party hereto, in its capacity as a Revolving Lender hereunder and in its capacity as a Revolving Lender under the Existing Credit Agreement, hereby consents to the amendments set forth herein.

SECTION 7.3 GOVERNING LAW.  THIS AMENDMENT AND ANY CLAIMS, CONTROVERSIES, DISPUTES, OR CAUSES OF ACTION (WHETHER ARISING UNDER CONTRACT LAW, TORT LAW OR OTHERWISE) BASED UPON OR RELATING TO THIS AMENDMENT, SHALL BE GOVERNED BY, AND CONSTRUED IN ACCORDANCE WITH, THE 

9

LAW OF THE STATE OF NEW YORK WITHOUT GIVING EFFECT TO ANY CHOICE OF LAW PRINCIPLES THAT WOULD APPLY THE LAWS OF ANOTHER JURISDICTION.

SECTION 7.4 SUBMISSION TO JURISDICTION; WAIVER OF VENUE; SERVICE OF PROCESS; WAIVER. EACH PARTY HERETO AGREES THAT SECTIONS 13.09(b), 13.09(c), 13.09(d), AND 13.09(e) OF THE CREDIT AGREEMENT SHALL APPLY TO THIS AMENDMENT MUTATIS MUTANDIS.

SECTION 7.5 No Advisory or Fiduciary Responsibility. Each party hereto agrees that Section 13.17 of the Credit Agreement shall apply to this Amendment mutatis mutandis.

SECTION 7.6 Severability.  Wherever possible, each provision of this Amendment shall be interpreted in such manner as to be effective and valid under applicable law, but if any provision of this Amendment shall be prohibited by or invalid under applicable law, such provision shall be ineffective only to the extent of such prohibition or invalidity, without invalidating the remainder of such provisions or the remaining provisions of this Amendment.

SECTION 7.7 Counterparts.  This Amendment may be executed in counterparts (and by different parties hereto on different counterparts), each of which shall constitute an original, but all of which when taken together shall constitute a single contract.  Delivery of an executed signature page to this Amendment by facsimile or other electronic transmission (including portable document format (“.pdf”) or similar format) shall be effective as delivery of a manually executed counterpart hereof. The words “execution,” “signed,” “signature,” “delivery,” and words of like import in or relating to this Amendment and any document to be signed in connection with this Amendment and the transactions contemplated hereby shall be deemed to include an electronic symbol or process attached to a contract or other record and adopted by a Person with the intent to sign, authenticate or accept such contract or record (each an “Electronic Signature”), deliveries or the keeping of records in electronic form, each of which shall be of the same legal effect, validity or enforceability as a manually executed signature, physical delivery thereof or the use of a paper-based recordkeeping system, as the case may be, to the extent and as provided for in any applicable law, including the Federal Electronic Signatures in Global and National Commerce Act, the New York State Electronic Signatures and Records Act, or any other similar state laws based on the Uniform Electronic Transactions Act; provided that nothing herein shall require the Administrative Agent to accept Electronic Signatures in any form or format without its prior written consent.  Without limiting the generality of the foregoing, the Borrower hereby (i) agrees that, for all purposes, including without limitation, in connection with any workout, restructuring, enforcement of remedies, bankruptcy proceedings or litigation among the Administrative Agent, the Lenders and the Credit Parties, electronic images of this Amendment or any other Credit Documents (in each case, including with respect to any signature pages thereto)  shall have the same legal effect, validity and enforceability as any paper original, and (ii) waives any argument, defense or right to contest the validity or enforceability of the Credit Documents based solely on the lack of paper original copies of any Credit Documents, including with respect to any signature pages thereto.

SECTION 7.8 Credit Document.  This Amendment shall constitute a “Credit Document”, as defined in the Credit Agreement.

SECTION 7.9 No Novation.  The parties hereto expressly acknowledge that it is not their intention that this Amendment or any of the other Credit Documents executed or delivered pursuant hereto constitute a novation of any of the obligations, covenants, or agreements contained in the Existing Credit Agreement or any other Credit Document, but rather constitute a modification thereof or 

10

supplement thereto pursuant to the terms contained herein.  The Existing Credit Agreement and the other Credit Documents, in each case as amended, modified, or supplemented hereby, shall be deemed to be continuing agreements among the parties thereto, and all documents, instruments, and agreements delivered, as well as all Liens created, pursuant to or in connection with the Existing Credit Agreement and the other Credit Documents shall remain in full force and effect, each in accordance with its terms (as amended, modified, or supplemented by this Amendment), unless such document, instrument, or agreement has otherwise been terminated or has expired in accordance with or pursuant to the terms of this Amendment or such document, instrument, or agreement or as otherwise agreed by the required parties hereto or thereto, it being understood that from after the occurrence of the Amendment No. 1 Effective Date, each reference in the Credit Documents to the “Credit Agreement,” “thereunder,” “thereof” (and each reference in the Credit Agreement to “this Agreement,” “hereunder,” or “hereof”) or words of like import shall mean and be a reference to the Credit Agreement as amended, modified or supplemented by this Amendment.

SECTION 7.10 Expenses.  Without duplication of any amounts required to be paid pursuant to Section 5.4, the Borrower agrees to reimburse the Administrative Agent for its reasonable and documented out-of-pocket expenses incurred by them in connection with this Amendment, including the reasonable and documented fees, charges and disbursements of Latham & Watkins LLP, counsel for the Administrative Agent.

[Remainder of page intentionally left blank]

11

IN WITNESS WHEREOF, the parties have caused this Amendment to be duly executed as of the day and year first above written, to be effective as of the Amendment No. 1 Effective Date.
Borrower:
TWIN RIVER WORLDWIDE HOLDINGS, INC.

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary

Guarantors:
TWIN RIVER MANAGEMENT GROUP, INC.

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary 

UTGR, INC.
By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary 
PREMIER ENTERTAINMENT BILOXI LLC
By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary

PREMIER FINANCE BILOXI CORP.

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary

[Signature Page to Amendment No. 1 to Credit Agreement]

JAMLAND, LLC

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary

TWIN RIVER-TIVERTON, LLC

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary

PREMIER ENTERTAINMENT III, LLC

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary 

DOVER DOWNS, INC.

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary 

DOVER DOWNS GAMING MANAGEMENT 
CORP.

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary 

PREMIER ENTERTAINMENT BLACK HAWK, 
LLC

By:  /s/ Craig L. Eaton   
Name: Craig L. Eaton
Title: Executive Vice President, General Counsel and Secretary 

 [Signature Page to Amendment No. 1 to Credit Agreement]

Acknowledged and Agreed by:

CITIZENS BANK, N.A., 
as Administrative Agent

By: /s/ SEAN MCWHINNIE   
Name: SEAN MCWHINNIE
Title: DIRECTOR
        

 [Signature Page to Amendment No. 1 to Credit Agreement]

CITIZENS BANK, N.A., as a Lender

By: /s/ SEAN MCWHINNIE   
Name: SEAN MCWHINNIE
Title: DIRECTOR

[Signature Page to Amendment No. 1 to Credit Agreement]

The Washington Trust Co., as a Lender

By: /s/ Robert J. O'Neill   
Name: Robert J. O'Neill 
Title: Vice President
(if a second signature is necessary)

By: 
Name: 
Title: 
[Signature Page to Amendment No. 1 to Credit Agreement]

Capital One, National Association, as a Lender

By: /s/ David Dale   
Name: David Dale
Title: Vice President
(if a second signature is necessary)

By:                            
Name: 
Title: 
[Signature Page to Amendment No. 1 to Credit Agreement]

TRUIST BANK, as a Lender

By: /s/ Ben Cumming   
Name: Ben Cumming
Title: Managing Director
[Signature Page to Amendment No. 1 to Credit Agreement]

DEUTSCHE BANK AG NEW YORK BRANCH, as a Lender

By: /s/ Philip Tancorra  
Name: Philip Tancorra
Title: Vice President
philip.tancorra@db.com
212-250-6576

By: /s/ Suzan Onal  
Name: Suzan Onal
Title: Vice President
suzan.onal@db.com
212-250-3174
[Signature Page to Amendment No. 1 to Credit Agreement]

FIFTH THIRD BANK, NATIONAL ASSOCIATION, as a Lender

By: /s/ Knight D. Kieffer   
Name: Knight D. Kieffer
Title: Managing Director
[Signature Page to Amendment No. 1 to Credit Agreement]

BANK OF AMERICA, N.A., as a Lender

By: /s/ Brian D. Corum   
Name: Brian D. Corum
Title: Managing Director
(if a second signature is necessary)

By:                            
Name: 
Title: 
[Signature Page to Amendment No. 1 to Credit Agreement]

CREDIT SUISSE AG, CAYMAN ISLANDS BRANCH, as a Lender

By: /s/ Whitney Gaston   
Name: Whitney Gaston
Title: Authorized Signatory

By: /s/ Kamal Shah                          
Name: Kamal Shah
Title: Authorized Signatory
[Signature Page to Amendment No. 1 to Credit Agreement]Exhibit 10.1

 

Mutual
Confidentiality Agreement

 

This
Mutual Confidentiality Agreement (Agreement) is made as of 21st April 2020 (“Effective Date”)
between AIM ImmunoTech with its address at 2117 SW Hwy 484 Ocala Fl 34473 (“AIM”), and UMN Pharma Inc with its
address at Nisso17 Bldg. 8F, 2-14-30, Shin-Yokohama, Kohoku-ku, Yokohama,
Kanagawa 222-0033, Japan (“UMN”) and National Institute of Infectious Diseases with its address Toyama
1-23-1, Shinjuku-ku Tokyo 162-8640, Japan (“NIID”), and Shionogi & Co., Ltd, with its address at 1-8, Doshomachi
3-chome Choku-ku, Osaka 541-0045 Japan (“SHIONOGI”) (each a Party and together the Parties). The terms Recipients
and Discloser refer to either Party, or the Parties, as the case may be.

 

RECITALS

 

WHEREAS,
all Parties (“Recipient”) will have access to and be provided certain confidential and proprietary information
of the other Parties (“Discloser”) for the purpose of evaluation and discussion for certain business relationship
concerning the COVID-19 vaccine among the Parties (“Purpose”); and

 

WHEREAS,
it is the desire of all Parties hereto that the confidentiality of all Discloser’s confidential information provided
to Recipients pursuant to this Agreement be maintained.

 

NOW,
THEREFORE, in consideration of the mutual covenants, conditions and promises herein contained, and other good and valuable
consideration the sufficiency of which is hereby acknowledged, the Parties hereto agree as follows:

 

Definition
of Confidential Information.

 

The
term “Confidential Information” shall be defined as all oral and written information (irrespective of the means of
the writing, e.g., hardcopy, fax, electronic writing, etc.) disclosed by Discloser or any employee, director, shareholder, agent,
representative or consultant of Discloser to Recipient relating to the following:

 

a.
Trade secrets, business, technical, financial and other confidential information pertaining to Discloser which is not generally
available to the public, including without limitation, information concerning the customers, suppliers, contacts, and employees
of Discloser; terms and conditions of Discloser’s agreements and arrangements with its customers, employees, suppliers and
others; customer and supplier list, information concerning Discloser’s manufacturing processes and methods, inventory pricing,
sales volumes and profits, procedures, marketing strategies, know-how, systems, developments and suggestions; data, drawings,
plans, documents and specifications; and all other information about Discloser’s operations and business (as presently conducted
and as proposed to be conducted); and

 

    	 	1	 

     

    

 

b.
Any and all information, agreements and documents in any form whatsoever regarding the capitalization, organization or ownership
of Discloser; and

 

c.
Any information generated or produced from Confidential Information given by Discloser to Recipient; provided however; it is expressly
understood and agreed that Confidential Information shall not include any information which at the time of disclosure to Recipient
is in the public domain, or information which, after disclosure to Recipient, becomes part of the public domain by publication
or otherwise without breach of this Agreement by Recipient, or information which Recipient obtained from third parties, provided
such information was not wrongly obtained by such third parties, or information which is independently developed by Recipient
without reference to, or use of, Confidential Information.

 

Products
currently owned by AIM include Ampligen and Alferon.

 

Recipient
agrees to maintain in confidence all Confidential Information disclosed by Discloser and to never divulge or disseminate said
Confidential Information, in whole or in part, to any third party, and to never make use of said Confidential Information other
than for the Purpose without the prior written consent of Discloser.

 

In
the event that Recipient has prepared or created, or does prepare or create, any document, memorandum, or other writing or determination
relative to, resulting from, or in any way utilizing, in whole or in part, any of the Confidential Information, such document,
research, or other writing or determination created or prepared by or for Recipient shall also constitute Confidential Information
and such information shall be governed by the provisions of this Agreement.

 

In
the event that any Confidential Information or any other information as described herein are required to be disclosed by any federal,
state or local governmental body or agency, having the legal authority to require such disclosure by Recipient, such disclosure
shall be in a manner which maintains confidentiality to the greatest extent permitted by law.

 

The
Confidential Information shall remain or become the property of Discloser at all times. No rights or licenses, expressed or implied,
are hereby granted to Recipient under any patents, copyrights or trade secrets of Discloser as a result of or related to this
Agreement.

 

Upon
request by Discloser, Recipient shall forthwith return to such Discloser all Confidential Information received by Recipient.

 

In
the event Recipient violates or breaches this Agreement, Discloser shall be entitled to all damages proximately caused thereby.
Further, Recipient acknowledges and agrees that monetary damages are unlikely to be an adequate remedy therefore, and without
waiving any right to monetary damages, it is expressly agreed that Discloser is authorized and entitled to obtain temporary and
permanent injunctive relief from any court of competent jurisdiction to restrain any breach of this Agreement, and any and all
actions of Recipient relative to the Confidential Information. Any and all rights and remedies shall be cumulative and in addition
to any other rights or remedies to which Discloser may be entitled.

 

    	 	2	 

     

    

 

In
the event of any action at law or equity, including arbitration to enforce or interpret any provision of this Agreement, the prevailing
Party shall be entitled to costs incurred including reasonable fees for expert witnesses and reasonable attorney’s fees.

 

The
Parties acknowledge that AIM is a public company and that any agreements including this Agreement that are reached between the
Parties and AIM will be considered material and as such AIM will be filing reports in AIMs 8K, 10K and 10Qs that address AIM contractual
relationships. This is an ongoing obligation that is required in order for AIM to adhere to SEC regulations.

 

This
Agreement constitutes the entire understanding of the Parties with regard to the subject matter hereof and may not be amended,
modified, supplemented or rescinded, except by a written instrument executed by all Parties hereto.

 

This
Agreement shall be governed by and construed in accordance with the laws of the State of New York, United States of America.

 

If
it shall subsequently be determined by a court of competent jurisdiction, that any portion of this Agreement is void, voidable
or unenforceable, (including, but not limited to, any time or geographical limitation) it shall not necessarily affect the validity
of the remaining provisions of this Agreement. Any such determination and its effect on this Agreement shall be to reform this
Agreement so as to allow the terms and provisions of this Agreement to apply to the maximum permitted by applicable law, and this
Agreement shall continue in full force and effect with regard to all other provisions.

 

This
Agreement may be executed as one or more counterparts, each of which will be deemed an original agreement, but all of which will
be considered one instrument and will become a binding agreement when one or more counterparts have been signed by all Parties.
A signed facsimile of this document or an electronically transmitted signature of the original signed document shall have the
same legal force and effect as an original of such signature and shall be treated as an original document for evidentiary purposes.

 

Recipient
hereby agrees to indemnify, defend and hold Discloser harmless from any and all liabilities, expenses, causes of action, claims
and liabilities arising out of or resulting, to any degree, from the unauthorized disclosure of Confidential Information of Discloser.

 

The
obligations set forth in this Agreement shall continue for a period of five years following disclosure of such Confidential Information
to Recipient.

 

    	 	3	 

     

    

 

IN
WITNESS WHEREOF, the Parties to this Agreement have duly executed it on the date set opposite their respective executions.

 

AIM
ImmunoTech Inc

2117
SW Highway 484

Ocala
FL 34473

 

	By:
    	/s/
Thomas K Equels	 	Date:
    	4/21//2020
	 	Thomas
    K Equels	 	 	 
	Title:
    	Chief
    Executive Officer	 	 	 

 

UMN
Pharma, Inc.

4-2-3,
Gosyonoyumoto, Akita

Akita
010-1415

Japan

 

	By:
    	/s/
    Fumihisa Nakata	 	Date:
    	4/22//2020
	 	Fumihisa Nakata	 	 	 
	Title:
    	Chief
    Executive Officer	 	 	 

 

NATIONAL
INSTITUTE OF INFECTIOUS DISEASES GAKUEN4-7-1,

Musashimurayama-shi,

Tokyo
208-0771,

Japan

 

	By:
    	/s/
    Hideki Hasegawa	 	Date:
	4/22//2020
	 	Hideki
    Hasegawa	 	 	 
	Title:
    	Director	 	 	 
	 	Influenza
    Virus Research Center	 	 	 

 

SHIONOGI
& CO., LTD.

1-8,
DOSHOMACHI 3-CHOME, CHUO-KU

OSAKA
541-0045,

JAPAN

 

	By:	/s/
    Ryuichi Kiyama	 	Date:	4/23//2020
	 	Ryuichi
    Kiyama, Ph.D.	 	 	 
	Title:	Senior
    Executive Officer	 	 	 
	 	Senior
    Vice President	 	 	 
	 	Pharmaceutical
    Research Division	 	 	 

 

    	 	4

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00308-of-00352.parquet"}]]